steve It is estimated that the Global Plasma Fractionation Market is expected to grow at a CAGR of around 7.1% during the predicted period, i.e., 2024-30. The demand for plasma-derived therapy has been increasing worldwide, owing to the commonness of rare disorders in the global population.
Moreover, the geriatric population has led to a substantial boost in the incidences of diseases such as neurological disorders, immunodeficiency, etc, which need plasma-derived therapies for treatment. As a result, the number of geriatric patients has been increasing, demand for plasma-derived therapeutic products has also increased, specifically coagulation, and immunoglobulins factors during the historical years. Furthermore, in response to the rising demand worldwide, companies specializing in plasma fractionation have significantly started investing in expanding their plasma therapy manufacturing facilities.
Augmentation of Plasma Fractionation Plants Gaining Traction
The rising positive results of plasma-derived drugs for autoimmune, and chronic, and other diseases have increased the demand for plasma fractionation products in the market. Also, the lucrative demand for plasma fractionation products has promoted global participants in the Plasma Fractionation Market, like Grifols, and Takeda Pharmaceuticals, to embark on a trend of establishing new manufacturing facilities worldwide.
As a result, this new trend will surely permit the companies to serve a huge audience range across different countries, which would further support their growth in the forthcoming years as well.
The Neurology Segment Dominates the Global Plasma Fractionation Market with Largest Market Share
Based on the Applications, the Global Plasma Fractionation Market is classified into several segments including – Neurology, Rheumatology, Immunology, Pulmonology, Hematology, Critical Care, and others. However, the Neurology segment occupies a major share of the plasma fractionation industry, owing to the effective, and rapid response provided by Intravenous immunoglobulins, in comparison to oral immune-suppressants, and steroids.
Moreover, the instances of neurological diseases and their related mortalities have been increasing, which further necessitated the requirement for its treatment options. Observing this mortality rate, the requirement for effective plasma therapy has improved, leading to companies focusing on the development and research of plasma-fractioned drugs essential to treat neurological disorders.
Top Market Participants of the Global Plasma Fractionation Industry
The recent report of MarkNtel Advisors on the Global Plasma Fractionation states that there are several players of this industry. However, the leading players of the plasma fractionation industry are – Australian Red Cross Lifeblood, S K Plasma, Plasma Gen Biosciences, Intas Pharmaceutical, Emergent Bio solutions, Takeda Pharmaceuticals, Bio Products Laboratory Ltd, Kedrion Biopharma Inc., Grifols S.A., CSL Limited, Aegros, Adma Biologics, Octapharma A.G., Biotest A.G., and others.
Latest Development of the Global Plasma Fractionation Market
In 2023, Bio Products Laboratory, declared the initiation of a strategic partnership with CSI Pharmacy to provide distribution rights to BPL’s immune globulin products Gammaplex.
North America Leads the Entire Plasma Fractionation Market
Geographically, the Global Plasma Fraction Market expands across – North America, Asia-Pacific, South America, Europe, and the Middle East & Africa. Among these, North America appeared as a leading player in the industry. The commonness of the dominance has been accredited to elevate awareness of the advantages of plasma, mainly among the Canadian, and the USA residents, along with the occurrence of respiratory diseases.
The presence of notable market players, the growing number of plasma collection facilities, and the effective supply chain for plasma collection, along with distribution all a played crucial role in supporting the expansion of the industry in the North American region.
Contact Us –
Call: 📞 +1 628 895 8081 +91 120 4278433
Email: 📧 sales@marknteladvisors.com
Visit to know more: 🌐 https://www.marknteladvisors.com
